Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

11.1%

3 terminated/withdrawn out of 27 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

26%

7 trials in Phase 3/4

Results Transparency

5%

1 of 21 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
10(45.5%)
Phase 3
7(31.8%)
Phase 1
4(18.2%)
N/A
1(4.5%)
22Total
Phase 2(10)
Phase 3(7)
Phase 1(4)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials
NCT04124497Phase 2Active Not Recruiting

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

Role: lead

NCT06682637Phase 2Withdrawn

Melflufen for Elderly Patients With Relapsed Myeloma

Role: lead

NCT05001087Recruiting

A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)

Role: lead

NCT05393024Completed

Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy

Role: lead

NCT04096066Phase 3Active Not Recruiting

A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

Role: lead

NCT01857115Phase 1Completed

Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)

Role: collaborator

NCT01093196Phase 3Completed

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Role: lead

NCT01091831Phase 3Completed

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

Role: lead

NCT02215980Phase 3Completed

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Role: lead

NCT00551928Phase 3Completed

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

Role: lead

NCT01081405Not ApplicableCompleted

Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation

Role: lead

NCT04492371Completed

COVID-19 Infection and Multiple Myeloma

Role: collaborator

NCT03406091Completed

Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients

Role: lead

NCT02056756Phase 1Completed

Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

Role: collaborator

NCT01190787Phase 2Completed

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

Role: collaborator

NCT01913730Phase 2Completed

Maintenance Therapy With Subcutaneous Bortezomib

Role: collaborator

NCT01346787Phase 2Completed

Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients

Role: collaborator

NCT02204241Phase 1Completed

Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients

Role: collaborator

NCT01063179Phase 3Completed

Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients

Role: lead

NCT01166113Phase 1Completed

Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide

Role: lead